# Development of Risk and Early Detection Biomarker for Small Cell Lung Cancer

> **NIH NIH U01** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2021 · $455,339

## Abstract

ABSTRACT
The goal of this proposal by a multi-disciplinary team at MD Anderson Cancer Center, the
University of Texas Southwestern Cancer Center and the University of Pittsburg Cancer Center
is to explore approaches based on circulating protein markers and autoantibodies to develop a
blood based marker panel to assess risk of harboring or developing small cell lung cancer
(SCLC). There are currently several established SCLC protein markers which individually lack
sufficient performance for early detection. Additionally, the applicant group has uncovered
several protein marker candidates through integrated analyses of mouse models and human
SCLC samples. To assess the potential of established and newly discovered candidate markers
to yield a combined panel of markers indicative of risk of harboring or developing SCLC,
validation studies will be conducted using plasma samples collected up to 5 years prior to a
diagnosis of SCLC, from participants in the large European Prospective Investigation into
Cancer and Nutrition (EPIC) and the Singapore Chinese Health Study (SCHS) cohorts.
Additonally, plasmas collected at the time of diagnosis of SCLC and post-treatment as well as
tissue molecular profiles will be interrogated to establish the biological relevance to candidates
to SCLC. Two approaches will be implemented to identify antigenic proteins and peptides that
induce autoantibodies that can be mined for SCLC early detection. One consisting of Ig bound
proteins in plasmas from SCLC cases and another novel approach consists of interrogating
whole genome derived peptide arrays for reactivity with aliquots of SCLC plasmas utilized for
validation of circulating proteins. The resulting combination of the most promising markers will
be further validated using pre-diagnostic SCLC samples and matched controls from the US
Prostate Lung Colon and Ovarian (PLCO) cohort. The applicant group has a substantial track
record of collaboration and expertise relevant to project objectives, with rigor in experimental
design for discovery and validation studies of lung cancer biomarkers.

## Key facts

- **NIH application ID:** 10242852
- **Project number:** 5U01CA213285-05
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** SAMIR M HANASH
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $455,339
- **Award type:** 5
- **Project period:** 2017-09-06 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242852

## Citation

> US National Institutes of Health, RePORTER application 10242852, Development of Risk and Early Detection Biomarker for Small Cell Lung Cancer (5U01CA213285-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10242852. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*